Assessment of community knowledge and awareness about ranitidine recall: a cross-sectional study

Abstract :

In April 2020, the Food and Drug Administration (FDA) requested immediate withdrawal of all prescription and over-the-counter ranitidine products. Ranitidine was recalled due to the presence of an unacceptable level of carcinogenic substance N-nitosodimethylamine (NDMA). Several pharmaceutical manufacturers have issued ranitidine product recalls including brand and generic ranitidine. FDA alerts patients to stop using ranitidine and advises them to talk with their health care professional about alternative treatments. In Libya, limited studies have been conducted to address people's awareness and knowledge in this regard. The objective of this study was to assess people's awareness and behavior toward ranitidine recall and related issues. A cross-sectional study was conducted in Zawia city for two months. An online questionnaire was distributed to 300 participants. Descriptive statistics analysis using Statistical Package for Social Sciences (SPSS) version 26.0 was used. The study found that more than half of the participants and their family members were likely to utilize ranitidine inappropriately. They seem to consume ranitidine more often without medical consultation. The findings also showed that 82.5% of the participants who were using ranitidine obtained the drug from pharmacies after the date of announcing ranitidine withdrawal from the market by the FDA. Furthermore, the vast majority of the participants were poorly informed or even had no information about ranitidine toxicity and their perception of the dangers of continued use of this drug is limited. The participants argued that pharmacists do not provide slightly information about dispensed ranitidine. In conclusion, all results reported as benefits of the participants in the study whereas the participant's perception and awareness increased when a brief notification regarding the reason for ranitidine toxicity was provided.

References

1. Ridgefield CT (2013) Boehringer Ingelheim Pharmaceuticals Inc (US). Zantac® launches innovative integrated marketing campaign to educate consumers on heartburn relief. ZAN-131047.
2. Strum WB (1983) Ranitidine. Journal of the American Medical Association (JAMA) 250 (14): 1894-1896.
3. Morgan KA, Ahlawat R (2021) Ranitidine. In StatPearls [Internet]. StatPearls Publishing LLC. PMID: 30422583.
4. U.S. Food and Drug Administration (2020). FDA requests removal of all ranitidine products (Zantac) from the market. FDA advises consumers, patients and health care professionals after new FDA studies show risk to public health. FDA news release. Published April 4, 2020.
5. Liteplo RG, Meek ME, Windle W (2002) N-nitrosodimethylamine. World Health Organization. WHO Library Cataloguing-in-Publication Data. ISBN: 92 4 153038 3.
6. International Agency for Research on Cancer (1987) Overall evaluations of carcinogenicity: an updating of IARC monographs, vol. 1 to 42. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans: Suppl. 7. IARC, 7: 1-440. ISBN: 978-92-832-1411-3.
7. Lips, RJ, Fennerty B, Fagan TC (1990) Clinical review of histamine-2 receptor antagonists. Archives of Internal Medicine. 150 (4): 745-751. PMID: 1970232.
8. Mirvish SS (1995) Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Letters. 93 (1): 17-48. doi: 10.1016/0304-3835(95)03786-V
9. Wagner JA, Dinh JC, Lightdale JR, Gold BD, Colombo JM (2021) Is this the end for ranitidine? NDMA presence continues to confound. Clinical and Translational Science. 14 (4): 1197-1200. doi: 10.1111/cts.12995
10. Matsuda J, Hinuma K, Tanida N, Tamura K, Ohno T, Kano M, Shimoyama T (1990) N-nitrosamines in gastric juice of patients with gastric ulcer before and during treatment with histamine H2-receptor antagonists. Gastroenterologia Japonica. 25 (2): 162-168. doi: 10.1007/BF02776810
11. Shen R, Andrews SA (2013) Formation of NDMA from ranitidine and sumatriptan: the role of pH. Water Research. 47 (2): 802-810. doi: 10.1016/j.watres.2012.11.004
12. Zeng T, Mitch WA (2016) Oral intake of ranitidine increases urinary excretion of N-nitrosodimethylamine. Carcinogenesis. 37 (6): 625-634. doi: 10.1093/carcin/bgw034
13. Michaud DS, Mysliwiec PA, Aldoori W, Willett WC, Giovannucci E (2004) Peptic ulcer disease and the risk of bladder cancer in a prospective study of male health professionals. Cancer Epidemiology and Biomarkers and Prevention. 13 (2): 250-254. doi: 10.1158/1055-9965.epi-03-0174
14. Vermeer IT, Engels LG, Pachen DM, Dallinga JW, Kleinjans JC, Van Maanen JM (2001) Intragastric volatile N-nitrosamines, nitrite, pH, and Helicobacter pylori during long-term treatment with omeprazole. Gastroenterology. 121 (3): 517-525. doi: 10.1053/gast.2001.27098
15. ATSDR (2021) Agency for Toxic Substance and Disease Registry. Public Health Statement for n-Nitrosodimethylamine. Available at https:// www.atsdr.cdc.gov/PHS/PHS.asp?id=882&tid= 173. Accessed January 21, 2021.
16. US Food and drug administration (2018) FDA’s role in drug recalls. Updated July 3, 2018. www.fda.gov/Drugs/ DrugSafety/DrugRecalls/ucm612550.htm. Accessed May, 13rd, 2022.
17. Kasulkar AA, Gupta M (2015) Self-medication practices among medical students of a private institute. Indian Journal of Pharmaceutical Sciences. 77 (2): 178-182. doi: 10.4103/0250-474x.15656
18. irtwhistle RV (1988) Antacid use in a family-practice population. Canadian Family Physician. 34: 1681-1683. PMID: 21253067.
19. Mabroukah AI, Einass RI (2021) Attitude of Libyan pharmacist in Western Region of Libya toward Zantac withdrawal. Libyan Journal of Medical Research. 15 (1): 1-15. doi: Nil.
20. Garjani A, Rahbar M, Ghafourian T, Maleki N, Garjani A, Salimnejad M, Aghajani H (2009) Relationship of pharmacist interaction with patient knowledge of dispensed drugs and patient satisfaction. Eastern Mediterranean Health Journal. 15 (4): 934-943. PMID: 20187545.
21. Begam RF, Ravikumar Y, Velmurugan R (2021) Awareness about FDA announcement on voluntary recall of ranitidine among physicians and pharmacists in and around Chennai, India: a cross-sectional study. Future Journal of Pharmaceutical Sciences. 7: 112. doi: 10.1186/s43094-021-00267-7
22. Hirko N, Edessa D (2017) Factors influencing the exit knowledge of patients for dispensed drugs at outpatient pharmacy of Hiwot Fana specialized university hospital, Eastern Ethiopia. Patient Preference and Adherence. 11: 205-212. doi: 10.2147/PPA.S128658

Citation :

Jaaida et al. (2022) Assessment of community knowledge and awareness about ranitidine recall: a cross-sectional study. Mediterr J Pharm Pharm Sci. 2 (2): 44-51. [Article number: 67]. https://doi.org/10.5281/zenodo.6780490